JP2011510929A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011510929A5 JP2011510929A5 JP2010544436A JP2010544436A JP2011510929A5 JP 2011510929 A5 JP2011510929 A5 JP 2011510929A5 JP 2010544436 A JP2010544436 A JP 2010544436A JP 2010544436 A JP2010544436 A JP 2010544436A JP 2011510929 A5 JP2011510929 A5 JP 2011510929A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrimido
- methoxy
- phenyl
- quinoline
- dione
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 21
- 150000003839 salts Chemical class 0.000 claims 10
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 4
- MUQKVPSLHRVESB-UHFFFAOYSA-N 3-(3-chlorophenyl)-7-methoxy-1-(1-methylsulfonylpiperidin-4-yl)pyrimido[5,4-c]quinoline-2,4-dione Chemical compound COC1=CC=CC2=C1N=CC(C(N(C=1C=C(Cl)C=CC=1)C1=O)=O)=C2N1C1CCN(S(C)(=O)=O)CC1 MUQKVPSLHRVESB-UHFFFAOYSA-N 0.000 claims 3
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 3
- NMCBQDCTQPGXHQ-UHFFFAOYSA-N 1-cyclopentyl-7-methoxy-3-(3-methylphenyl)pyrimido[5,4-c]quinoline-2,4-dione Chemical compound COC1=CC=CC2=C1N=CC(C(N(C=1C=C(C)C=CC=1)C1=O)=O)=C2N1C1CCCC1 NMCBQDCTQPGXHQ-UHFFFAOYSA-N 0.000 claims 2
- XBMCCMKXNQMPDO-UHFFFAOYSA-N 1-cyclopentyl-7-methoxy-3-(4-methylthiophen-2-yl)pyrimido[5,4-c]quinoline-2,4-dione Chemical compound COC1=CC=CC2=C1N=CC(C(N(C=1SC=C(C)C=1)C1=O)=O)=C2N1C1CCCC1 XBMCCMKXNQMPDO-UHFFFAOYSA-N 0.000 claims 2
- IISWCMIDUMTUPJ-UHFFFAOYSA-N 3-(3-chlorophenyl)-1-(1-ethylsulfonylpiperidin-4-yl)-7-methoxypyrimido[5,4-c]quinoline-2,4-dione Chemical compound C1CN(S(=O)(=O)CC)CCC1N1C(=O)N(C=2C=C(Cl)C=CC=2)C(=O)C2=CN=C3C(OC)=CC=CC3=C21 IISWCMIDUMTUPJ-UHFFFAOYSA-N 0.000 claims 2
- QBTZSDNOQVLDBB-MRXNPFEDSA-N 3-(3-chlorophenyl)-7-methoxy-1-[(3r)-1-methylsulfonylpyrrolidin-3-yl]pyrimido[5,4-c]quinoline-2,4-dione Chemical compound COC1=CC=CC2=C1N=CC(C(N(C=1C=C(Cl)C=CC=1)C1=O)=O)=C2N1[C@@H]1CCN(S(C)(=O)=O)C1 QBTZSDNOQVLDBB-MRXNPFEDSA-N 0.000 claims 2
- QBTZSDNOQVLDBB-INIZCTEOSA-N 3-(3-chlorophenyl)-7-methoxy-1-[(3s)-1-methylsulfonylpyrrolidin-3-yl]pyrimido[5,4-c]quinoline-2,4-dione Chemical compound COC1=CC=CC2=C1N=CC(C(N(C=1C=C(Cl)C=CC=1)C1=O)=O)=C2N1[C@H]1CCN(S(C)(=O)=O)C1 QBTZSDNOQVLDBB-INIZCTEOSA-N 0.000 claims 2
- UXQHERGWFNFMGT-UHFFFAOYSA-N 1-cyclopentyl-3-(2,3-dimethylphenyl)-7-methoxypyrimido[5,4-c]quinoline-2,4-dione Chemical compound COC1=CC=CC2=C1N=CC(C(N(C=1C(=C(C)C=CC=1)C)C1=O)=O)=C2N1C1CCCC1 UXQHERGWFNFMGT-UHFFFAOYSA-N 0.000 claims 1
- CSURRMSKKGUPBQ-UHFFFAOYSA-N 1-cyclopentyl-3-(2,5-dimethylphenyl)-7-methoxypyrimido[5,4-c]quinoline-2,4-dione Chemical compound COC1=CC=CC2=C1N=CC(C(N(C=1C(=CC=C(C)C=1)C)C1=O)=O)=C2N1C1CCCC1 CSURRMSKKGUPBQ-UHFFFAOYSA-N 0.000 claims 1
- XNSUXHIVHKZNQR-UHFFFAOYSA-N 1-cyclopentyl-3-(3,4-dimethylphenyl)-7-methoxypyrimido[5,4-c]quinoline-2,4-dione Chemical compound COC1=CC=CC2=C1N=CC(C(N(C=1C=C(C)C(C)=CC=1)C1=O)=O)=C2N1C1CCCC1 XNSUXHIVHKZNQR-UHFFFAOYSA-N 0.000 claims 1
- ATMBZUZOUPYZSJ-UHFFFAOYSA-N 1-cyclopentyl-3-(3,5-dimethylphenyl)-7-methoxypyrimido[5,4-c]quinoline-2,4-dione Chemical compound COC1=CC=CC2=C1N=CC(C(N(C=1C=C(C)C=C(C)C=1)C1=O)=O)=C2N1C1CCCC1 ATMBZUZOUPYZSJ-UHFFFAOYSA-N 0.000 claims 1
- PUVOZFSDIYNDGR-UHFFFAOYSA-N 1-cyclopentyl-3-(3-ethylphenyl)-7-methoxypyrimido[5,4-c]quinoline-2,4-dione Chemical compound CCC1=CC=CC(N2C(C3=CN=C4C(OC)=CC=CC4=C3N(C3CCCC3)C2=O)=O)=C1 PUVOZFSDIYNDGR-UHFFFAOYSA-N 0.000 claims 1
- OOUYBBSDYRMPDH-UHFFFAOYSA-N 1-cyclopentyl-3-(3-fluoro-4-methylphenyl)-7-methoxypyrimido[5,4-c]quinoline-2,4-dione Chemical compound COC1=CC=CC2=C1N=CC(C(N(C=1C=C(F)C(C)=CC=1)C1=O)=O)=C2N1C1CCCC1 OOUYBBSDYRMPDH-UHFFFAOYSA-N 0.000 claims 1
- BHEJVSJTYQYCBB-UHFFFAOYSA-N 1-cyclopentyl-3-(3-fluorophenyl)-7-methoxypyrimido[5,4-c]quinoline-2,4-dione Chemical compound COC1=CC=CC2=C1N=CC(C(N(C=1C=C(F)C=CC=1)C1=O)=O)=C2N1C1CCCC1 BHEJVSJTYQYCBB-UHFFFAOYSA-N 0.000 claims 1
- NLIFNZBMILAJFA-UHFFFAOYSA-N 1-cyclopentyl-3-(4-fluoro-3-methylphenyl)-7-methoxypyrimido[5,4-c]quinoline-2,4-dione Chemical compound COC1=CC=CC2=C1N=CC(C(N(C=1C=C(C)C(F)=CC=1)C1=O)=O)=C2N1C1CCCC1 NLIFNZBMILAJFA-UHFFFAOYSA-N 0.000 claims 1
- LYUZLPVTIXFQQE-UHFFFAOYSA-N 1-cyclopentyl-7-methoxy-3-(2-methylphenyl)pyrimido[5,4-c]quinoline-2,4-dione Chemical compound COC1=CC=CC2=C1N=CC(C(N(C=1C(=CC=CC=1)C)C1=O)=O)=C2N1C1CCCC1 LYUZLPVTIXFQQE-UHFFFAOYSA-N 0.000 claims 1
- FOCBXVWTIKRGEO-UHFFFAOYSA-N 1-cyclopentyl-7-methoxy-3-(4-methylphenyl)pyrimido[5,4-c]quinoline-2,4-dione Chemical compound COC1=CC=CC2=C1N=CC(C(N(C=1C=CC(C)=CC=1)C1=O)=O)=C2N1C1CCCC1 FOCBXVWTIKRGEO-UHFFFAOYSA-N 0.000 claims 1
- RTYXYVDCINKRTD-UHFFFAOYSA-N 1-cyclopentyl-7-methoxy-3-[5-methyl-2-(trifluoromethyl)furan-3-yl]pyrimido[5,4-c]quinoline-2,4-dione Chemical compound COC1=CC=CC2=C1N=CC(C(N(C1=C(OC(C)=C1)C(F)(F)F)C1=O)=O)=C2N1C1CCCC1 RTYXYVDCINKRTD-UHFFFAOYSA-N 0.000 claims 1
- RSCKXYMEBLRFKV-UHFFFAOYSA-N 1-cyclopentyl-7-methoxy-3-phenylpyrimido[5,4-c]quinoline-2,4-dione Chemical compound COC1=CC=CC2=C1N=CC(C(N(C=1C=CC=CC=1)C1=O)=O)=C2N1C1CCCC1 RSCKXYMEBLRFKV-UHFFFAOYSA-N 0.000 claims 1
- WEWXZCSTWDNTEE-UHFFFAOYSA-N 1-cyclopentyl-7-methoxy-3-thiophen-2-ylpyrimido[5,4-c]quinoline-2,4-dione Chemical compound COC1=CC=CC2=C1N=CC(C(N(C=1SC=CC=1)C1=O)=O)=C2N1C1CCCC1 WEWXZCSTWDNTEE-UHFFFAOYSA-N 0.000 claims 1
- AYFGDEWSNGOXQG-UHFFFAOYSA-N 1-cyclopentyl-7-methoxy-3-thiophen-3-ylpyrimido[5,4-c]quinoline-2,4-dione Chemical compound COC1=CC=CC2=C1N=CC(C(N(C1=CSC=C1)C1=O)=O)=C2N1C1CCCC1 AYFGDEWSNGOXQG-UHFFFAOYSA-N 0.000 claims 1
- BOWZLOCTDYTWKK-UHFFFAOYSA-N 3-(3-chlorophenyl)-1-cyclohexyl-7-methoxypyrimido[5,4-c]quinoline-2,4-dione Chemical compound COC1=CC=CC2=C1N=CC(C(N(C=1C=C(Cl)C=CC=1)C1=O)=O)=C2N1C1CCCCC1 BOWZLOCTDYTWKK-UHFFFAOYSA-N 0.000 claims 1
- JUZPJZSDHMNYSS-UHFFFAOYSA-N 3-(3-chlorophenyl)-1-cyclopentyl-7-methoxypyrimido[5,4-c]quinoline-2,4-dione Chemical compound COC1=CC=CC2=C1N=CC(C(N(C=1C=C(Cl)C=CC=1)C1=O)=O)=C2N1C1CCCC1 JUZPJZSDHMNYSS-UHFFFAOYSA-N 0.000 claims 1
- XUUYDWPUWOPVDD-UHFFFAOYSA-N 3-(3-chlorophenyl)-7-methoxy-1-(1-propan-2-ylsulfonylpiperidin-4-yl)pyrimido[5,4-c]quinoline-2,4-dione Chemical compound COC1=CC=CC2=C1N=CC(C(N(C=1C=C(Cl)C=CC=1)C1=O)=O)=C2N1C1CCN(S(=O)(=O)C(C)C)CC1 XUUYDWPUWOPVDD-UHFFFAOYSA-N 0.000 claims 1
- PEPXWYFVYAYCEQ-OAHLLOKOSA-N 3-(3-chlorophenyl)-7-methoxy-1-[(3r)-pyrrolidin-3-yl]pyrimido[5,4-c]quinoline-2,4-dione Chemical compound COC1=CC=CC2=C1N=CC(C(N(C=1C=C(Cl)C=CC=1)C1=O)=O)=C2N1[C@@H]1CCNC1 PEPXWYFVYAYCEQ-OAHLLOKOSA-N 0.000 claims 1
- PEPXWYFVYAYCEQ-HNNXBMFYSA-N 3-(3-chlorophenyl)-7-methoxy-1-[(3s)-pyrrolidin-3-yl]pyrimido[5,4-c]quinoline-2,4-dione Chemical compound COC1=CC=CC2=C1N=CC(C(N(C=1C=C(Cl)C=CC=1)C1=O)=O)=C2N1[C@H]1CCNC1 PEPXWYFVYAYCEQ-HNNXBMFYSA-N 0.000 claims 1
- CZVSIRAXWOPYTM-UHFFFAOYSA-N 3-(3-chlorophenyl)-7-methoxy-1-piperidin-4-ylpyrimido[5,4-c]quinoline-2,4-dione Chemical compound COC1=CC=CC2=C1N=CC(C(N(C=1C=C(Cl)C=CC=1)C1=O)=O)=C2N1C1CCNCC1 CZVSIRAXWOPYTM-UHFFFAOYSA-N 0.000 claims 1
- HTJQZSKMGBFHSG-SAABIXHNSA-N C1C[C@@H](C(=O)OCC)CC[C@@H]1N1C(=O)N(C=2C=C(Cl)C=CC=2)C(=O)C2=CN=C3C(OC)=CC=CC3=C21 Chemical compound C1C[C@@H](C(=O)OCC)CC[C@@H]1N1C(=O)N(C=2C=C(Cl)C=CC=2)C(=O)C2=CN=C3C(OC)=CC=CC3=C21 HTJQZSKMGBFHSG-SAABIXHNSA-N 0.000 claims 1
- VLSIAPYZDCCBPU-KOMQPUFPSA-N COC1=CC=CC2=C1N=CC(C(N(C=1C=C(Cl)C=CC=1)C1=O)=O)=C2N1[C@H]1CC[C@H](C(O)=O)CC1 Chemical compound COC1=CC=CC2=C1N=CC(C(N(C=1C=C(Cl)C=CC=1)C1=O)=O)=C2N1[C@H]1CC[C@H](C(O)=O)CC1 VLSIAPYZDCCBPU-KOMQPUFPSA-N 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims 1
- NZIWLTJRFGAVRA-UHFFFAOYSA-N methyl 4-[3-(3-chlorophenyl)-7-methoxy-2,4-dioxopyrimido[5,4-c]quinolin-1-yl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC)CCC1N1C(=O)N(C=2C=C(Cl)C=CC=2)C(=O)C2=CN=C3C(OC)=CC=CC3=C21 NZIWLTJRFGAVRA-UHFFFAOYSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- GMEQCFSPZBKXJY-UHFFFAOYSA-N propan-2-yl 4-[3-(3-chlorophenyl)-7-methoxy-2,4-dioxopyrimido[5,4-c]quinolin-1-yl]piperidine-1-carboxylate Chemical compound COC1=CC=CC2=C1N=CC(C(N(C=1C=C(Cl)C=CC=1)C1=O)=O)=C2N1C1CCN(C(=O)OC(C)C)CC1 GMEQCFSPZBKXJY-UHFFFAOYSA-N 0.000 claims 1
- CTKRVYLHFHYHOK-GOSISDBHSA-N tert-butyl (3r)-3-[3-(3-chlorophenyl)-7-methoxy-2,4-dioxopyrimido[5,4-c]quinolin-1-yl]pyrrolidine-1-carboxylate Chemical compound COC1=CC=CC2=C1N=CC(C(N(C=1C=C(Cl)C=CC=1)C1=O)=O)=C2N1[C@@H]1CCN(C(=O)OC(C)(C)C)C1 CTKRVYLHFHYHOK-GOSISDBHSA-N 0.000 claims 1
- WLPGFXATLLKQGT-UHFFFAOYSA-N tert-butyl 4-[3-(3-chlorophenyl)-7-methoxy-2,4-dioxopyrimido[5,4-c]quinolin-1-yl]piperidine-1-carboxylate Chemical compound COC1=CC=CC2=C1N=CC(C(N(C=1C=C(Cl)C=CC=1)C1=O)=O)=C2N1C1CCN(C(=O)OC(C)(C)C)CC1 WLPGFXATLLKQGT-UHFFFAOYSA-N 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2361708P | 2008-01-25 | 2008-01-25 | |
| US61/023,617 | 2008-01-25 | ||
| PCT/US2009/031819 WO2009094528A1 (en) | 2008-01-25 | 2009-01-23 | TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-α SYNTHESIS AND AS PDE4 INHIBITORS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011510929A JP2011510929A (ja) | 2011-04-07 |
| JP2011510929A5 true JP2011510929A5 (enExample) | 2012-03-08 |
| JP5406215B2 JP5406215B2 (ja) | 2014-02-05 |
Family
ID=40901439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010544436A Active JP5406215B2 (ja) | 2008-01-25 | 2009-01-23 | ＴＮＦ−α合成の調節因子及びＰＤＥ４阻害剤としての三環系化合物 |
Country Status (16)
| Country | Link |
|---|---|
| US (10) | US7964608B2 (enExample) |
| EP (1) | EP2244574B1 (enExample) |
| JP (1) | JP5406215B2 (enExample) |
| KR (1) | KR101709141B1 (enExample) |
| CN (1) | CN101925301B (enExample) |
| AU (1) | AU2009206368B2 (enExample) |
| BR (1) | BRPI0906809A2 (enExample) |
| CA (1) | CA2711576C (enExample) |
| EA (1) | EA018462B1 (enExample) |
| ES (1) | ES2523169T3 (enExample) |
| IL (1) | IL206854A (enExample) |
| MA (1) | MA32035B1 (enExample) |
| MX (1) | MX2010007768A (enExample) |
| NZ (1) | NZ586695A (enExample) |
| WO (1) | WO2009094528A1 (enExample) |
| ZA (1) | ZA201004818B (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7964608B2 (en) | 2008-01-25 | 2011-06-21 | High Point Pharmaceuticals, Llc | Tricyclic compounds as modulators of TNF-α synthesis |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| AR090100A1 (es) * | 2012-02-21 | 2014-10-22 | Celgene Corp | Procesos para la preparacion de la (s)-1-(3-etoxi-4-metoxifenil)-2-metanosulfoniletilamina |
| US9611267B2 (en) | 2012-06-13 | 2017-04-04 | Incyte Holdings Corporation | Substituted tricyclic compounds as FGFR inhibitors |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| DK2950649T3 (da) | 2013-02-01 | 2020-05-04 | Wellstat Therapeutics Corp | Aminforbindelser med antiinflammations-, antisvampe-, antiparasit- og anticanceraktivitet |
| TWI649318B (zh) | 2013-04-19 | 2019-02-01 | 英塞特控股公司 | 作為ｆｇｆｒ抑制劑之雙環雜環 |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| AU2016219822B2 (en) | 2015-02-20 | 2020-07-09 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| BR112017026191B1 (pt) * | 2015-06-17 | 2023-10-10 | Pfizer Inc | Compostos tricíclicos inibidores de fosfodiesterase, sua composição farmacêutica e uso dos mesmos |
| WO2017089347A1 (en) | 2015-11-25 | 2017-06-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| TW201946630A (zh) | 2018-05-04 | 2019-12-16 | 美商英塞特公司 | Fgfr抑制劑之鹽 |
| ES2991427T3 (es) | 2018-05-04 | 2024-12-03 | Incyte Corp | Formas sólidas de un inhibidor de FGFR y procedimientos para preparar las mismas |
| CN109705037A (zh) * | 2019-01-24 | 2019-05-03 | 广西师范大学 | 4-氨基喹啉-3-甲酸酯衍生物及其制备方法和应用 |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| KR102766496B1 (ko) | 2019-08-09 | 2025-02-10 | 주식회사 엘지에너지솔루션 | 연쇄발화 방지를 위한 에너지 드레인 저항체를 구비한 배터리 팩 |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| GEAP202415945A (en) | 2019-10-14 | 2024-04-25 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| AU2020395185A1 (en) | 2019-12-04 | 2022-06-02 | Incyte Corporation | Derivatives of an FGFR inhibitor |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CN111808098B (zh) * | 2020-06-29 | 2021-08-24 | Vtv治疗有限责任公司 | 喹啉衍生物，其药学上可接受的盐及其使用方法 |
| AU2021315488A1 (en) * | 2020-07-28 | 2023-03-23 | Vtv Therapeutics Llc | Crystalline form of hydrochloride salt of quinoline derivative |
| CN116529247A (zh) * | 2020-07-28 | 2023-08-01 | 维特卫治疗有限责任公司 | 喹啉衍生物的盐酸盐的晶型 |
| EP4323405A1 (en) | 2021-04-12 | 2024-02-21 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| AR126101A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
| CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| CN116262750A (zh) * | 2021-12-15 | 2023-06-16 | 上海翊石医药科技有限公司 | 一种芳杂环类化合物及其制备方法和用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO162019C (no) | 1983-11-23 | 1989-10-25 | Fujisawa Pharmaceutical Co | Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrimidoiskinolinderivater. |
| US4927820A (en) | 1988-11-25 | 1990-05-22 | Hoechst Roussel Pharmaceuticals Inc. | Fused heterocyclic derivatives of 1,2,3,4-tetrahydroacridine |
| JPH0741479A (ja) * | 1993-07-28 | 1995-02-10 | Taisho Pharmaceut Co Ltd | ７−アザプテリジン類およびその製造方法 |
| WO1997044322A1 (en) * | 1996-05-20 | 1997-11-27 | Darwin Discovery Limited | Quinoline sulfonamides as tnf inhibitors and as pde-iv inhibitors |
| US6930101B1 (en) * | 1999-05-17 | 2005-08-16 | The Regents Of The University Of California | Thiazolopyrimidines useful as TNFα inhibitors |
| US20030207845A1 (en) | 2001-02-08 | 2003-11-06 | Keating Elizabeth T. | Method and compositions for treating an inflammatory disease |
| NZ532278A (en) | 2001-09-19 | 2006-02-24 | Altana Pharma Ag | Combination of a PDE inhibitor and an NSAID |
| TW200306192A (en) | 2002-01-18 | 2003-11-16 | Bristol Myers Squibb Co | Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors |
| PL193012B1 (pl) * | 2003-06-09 | 2007-01-31 | Univ Medyczny | 3-podstawiony 1,2,3,4-tetrahydropirymido[5,4-c]cynnolin-2,4-dion i 3-podstawiony 1,2,3,4-tetrahydropirymido[5,4-c]chinolin-2,4-dion oraz sposób otrzymywania 3-podstawionego 1,2,3,4-tetrahydropirymido[5,4-c]cynnolin-2,4-dionu i 3-podstawionego 1,2,3,4-tetrahydropirymido[5,4-c]chinolin-2,4-dionu |
| TW200726767A (en) * | 2005-07-04 | 2007-07-16 | Astrazeneca Ab | Chemical compounds 2 |
| US7964608B2 (en) * | 2008-01-25 | 2011-06-21 | High Point Pharmaceuticals, Llc | Tricyclic compounds as modulators of TNF-α synthesis |
| JP2012519159A (ja) | 2009-02-27 | 2012-08-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｐｄｅ４阻害剤及びｎｓａｉｄを含有する複合薬 |
| CA2753604A1 (en) | 2009-02-27 | 2010-09-02 | Boehringer Ingelheim International Gmbh | Drug combinations containing pde4-inhibitors and nsaids |
| JP2013523792A (ja) | 2010-04-08 | 2013-06-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｐｄｅ４阻害剤及びｅｐ４受容体アンタゴニストを含有する医薬の組み合わせ |
| EP2555773A1 (de) | 2010-04-08 | 2013-02-13 | Boehringer Ingelheim International GmbH | Arzneimittelkombinationen enthaltend pde4-inhibitoren und ep4-rezeptor-antagonisten |
-
2009
- 2009-01-23 US US12/532,861 patent/US7964608B2/en active Active
- 2009-01-23 JP JP2010544436A patent/JP5406215B2/ja active Active
- 2009-01-23 KR KR1020107017176A patent/KR101709141B1/ko active Active
- 2009-01-23 BR BRPI0906809-0A patent/BRPI0906809A2/pt not_active Application Discontinuation
- 2009-01-23 AU AU2009206368A patent/AU2009206368B2/en active Active
- 2009-01-23 ES ES09704760.9T patent/ES2523169T3/es active Active
- 2009-01-23 NZ NZ586695A patent/NZ586695A/en not_active IP Right Cessation
- 2009-01-23 EP EP09704760.9A patent/EP2244574B1/en active Active
- 2009-01-23 WO PCT/US2009/031819 patent/WO2009094528A1/en not_active Ceased
- 2009-01-23 CN CN200980102961.0A patent/CN101925301B/zh active Active
- 2009-01-23 EA EA201070884A patent/EA018462B1/ru not_active IP Right Cessation
- 2009-01-23 CA CA2711576A patent/CA2711576C/en active Active
- 2009-01-23 MX MX2010007768A patent/MX2010007768A/es active IP Right Grant
-
2010
- 2010-07-07 IL IL206854A patent/IL206854A/en active IP Right Grant
- 2010-07-08 ZA ZA2010/04818A patent/ZA201004818B/en unknown
- 2010-07-23 MA MA33045A patent/MA32035B1/fr unknown
-
2011
- 2011-03-04 US US13/040,382 patent/US8853226B2/en active Active
-
2012
- 2012-03-02 US US13/410,628 patent/US8329715B2/en active Active
-
2014
- 2014-09-04 US US14/477,302 patent/US9163022B2/en active Active
-
2015
- 2015-09-10 US US14/850,012 patent/US9393245B2/en active Active
-
2016
- 2016-06-16 US US15/184,392 patent/US9687489B2/en active Active
-
2017
- 2017-05-22 US US15/600,942 patent/US9833457B2/en active Active
- 2017-11-01 US US15/800,794 patent/US10085990B2/en active Active
-
2018
- 2018-08-27 US US16/113,327 patent/US10391097B2/en active Active
-
2019
- 2019-07-10 US US16/507,219 patent/US10568888B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011510929A5 (enExample) | ||
| JP5411300B2 (ja) | 可溶性グアニレートシクラーゼ活性化剤 | |
| US11759454B2 (en) | Diazole lactams | |
| NZ601656A (en) | Pyridyloxyindoles inhibitors of VEGF-R2 and use thereof for treatment of disease | |
| JP2017525668A5 (enExample) | ||
| JP2012507525A5 (enExample) | ||
| JP2011528658A5 (enExample) | ||
| RU2015106787A (ru) | Замещенные пирролы, активные в качестве ингибиторов киназ | |
| JP2008525502A5 (enExample) | ||
| CZ300148B6 (cs) | Derivát substituovaného benzimidazolu, zpusob jeho prípravy a jeho použití | |
| JP2012525431A5 (enExample) | ||
| KR910009705A (ko) | 수용성이 개선된 이미다조[4,5-b] 퀴놀리닐 옥시알칸산 아미드 | |
| JP2008510828A5 (enExample) | ||
| JPWO2000039116A1 (ja) | アミノピラゾール誘導体 | |
| JP2011506480A5 (enExample) | ||
| RU2012129882A (ru) | Соединение | |
| JP2007519695A5 (enExample) | ||
| RU2011121665A (ru) | Производные 7-гидроксибензимидазол-4-илметанона и содержащие их ингибиторы рвк | |
| AR107633A1 (es) | Procedimiento para la preparación del ácido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]-3-oxo-5,6,8,8a-tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxílico | |
| JP2006516610A5 (enExample) | ||
| JP2014521620A5 (enExample) | ||
| JP2008519087A5 (enExample) | ||
| JP2005526794A5 (ja) | ベンズイミダゾールおよびマイトジェン活性化およびｒｈｏキナーゼ阻害剤としてのその使用 | |
| CN104918921A (zh) | 二唑酰胺 | |
| JP2009543794A5 (enExample) |